//www.makeeyeware.comInsight
//www.makeeyeware.comTaplow
//www.makeeyeware.comKnowledge
  • News
  • Cases
  • Downloads
Taplow News- 2nd Pandemic Business Overview
20.04.2020

Taplow News- 2nd Pandemic Business Overview

Taplow Group – Pandemic Business OverviewThe global pandemic has seen businesses affected across every sector, in all parts of the world....
Navigating the Post Pandemic World Order - Our Take
16.04.2020

Navigating the Post Pandemic World Order - Our Take

As the world battles Covid-19, countries have triggered containment measures that have half of humanity in lock down. Not to mention the economic...
Taplow News- Pandemic Business Overview
06.04.2020

Taplow News- Pandemic Business Overview

COVID-19, the global pandemic has been affecting businesses across every sector, in all parts of the world. Taplow partners have all come together...
First 4 5 6 7 8 9 10 11 12 13 Last

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contactSangeeta Sabharwal, India

    点击这里
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    点击这里
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    点击这里
  • BUSINESS CYCLES

    人力资本提供了机遇和挑战:

    点击这里